Seeking Alpha

Endo Health Solutions (ENDP -2.6%) appears to have stabilized today, albeit lower, following a...

Endo Health Solutions (ENDP -2.6%) appears to have stabilized today, albeit lower, following a couple of trading halts on volatility just prior to Friday's close after the FDA denied its petition to halt generic competition to its painkiller Opana ER on safety grounds. The ruling will mean a big hit to earnings next quarter, and likely lead exploring options to mitigate the damage. Jefferies says the FDA was wrong, and acted "irrationally inconsistent" in its decision. Nonetheless, the firm lowers its price target on the shares from $47.00 to $37.00.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)